A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Clinical trial NCT05463731 · COMPLETED

Trial details

NCT number: NCT05463731
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer's Disease

Start date: 2022-08-01
Primary completion: 2024-04-24
Enrollment: 1667

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.